Catheter management in hemodialysis patients: Delivering adequate flow

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 1, 2011, Pages 227-234

  Besarab, Anatole ^a   Pandey, Rahul ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ARTERIOVENOUS FISTULA; CATHETER INFECTION; CATHETER OCCLUSION; CATHETER THROMBOSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INDWELLING CATHETER; INTRAVASCULAR CATHETER; KIDNEY FAILURE; MORBIDITY; MORTALITY; REVIEW; UNITED STATES; VASCULAR ACCESS;

ANTICOAGULANTS; CATHETERS, INDWELLING; HUMANS; RENAL DIALYSIS; THROMBOSIS; VASCULAR PATENCY;

EID: 79251515801     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04840610     Document Type: Review

References (81)

1. U.S. Renal Data System: USRDS 2008 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
2. National Kidney Foundation: Clinical practice guidelines for vascular access: 2006 update. Am J Kidney Dis 48[Suppl 1]: S176-S285, 2006
3. Bhola C, Lok CE: Central venous catheters: Optimizing the suboptimal. Nephrol News Issues 22: 38-44, 2008
4. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61: 305-316, 2002
5. U.S. Renal Data System: USRDS 2008 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States, Bethesda MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008
6. Mendelssohn DC, Ethier J: Hemodialysis vascular access problems in Canada: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). Nephrol Dial Transplant 21: 721-728, 2006
7. Ash SR: Advances in tunneled central venous catheters for dialysis: Design and performance. Semin Dial 21: 504-515, 2008
8. Wang J, LaBerge JM, Chertow GM, Kerlan RK, Wilson MW, Gordon RL: Tesio catheter access for long-term maintenance hemodialysis. Radiology 241: 284-290, 2006
9. Besarab A, Brouwer D: Aligning hemodialysis treatment practices with the National Kidney Foundation's K/DOQI vascular access guidelines. Dial Transplant 33: 694-702, 2004
10. Moist LM, Trpeski L, Na Y, Lok CE: Increased hemodialysis catheter use in Canada and associated mortality risk: Data from the Canadian Organ Replacement Registry 2001-2004. Clin J Am Soc Nephrol 3: 1726-1732, 2008
11. Sands JJ: Vascular access: The past, present and future. Blood Purif 27: 22-27, 2009
12. Owen WF Jr., Chertow GM, Lazarus JM, Lowrie EG: Dose of hemodialysis and survival: Differences by race and sex. JAMA 280: 1764-1768, 1998
13. Balwit A: Clinical and Economic Issues in Vascular Access for Hemodialysis, Madison WI, Ahrens Balwit & Associates Inc., 2002
14. Hakim RM, Breyer J, Ismail N, Schulman G: Effects of dose of hemodialysis on morbidity and mortality. Am J Kidney Dis 23: 661-669, 1994
15. Rocco MV, Bleyer AJ, Burkart JM: Utilization of inpatient and outpatient resources for the management of hemodialysis access complications. Am J Kidney Dis 28: 250-256, 1996
16. Sehgal AR, Dor A, Tsai AC: Morbidity and cost implications of inadequate hemodialysis. Am J Kidney Dis 37: 1223-1231, 2001
17. Leblanc M, Bosc JY, Paganini EP, Canaud B: Central venous dialysis catheter dysfunction. Adv Ren Replace Ther 4: 377-389, 1997
18. Whitman ED: Complications associated with the use of central venous access devices. Curr Probl Surg 33: 319-378, 1996
19. Fux CA, Uehlinger D, Bodmer T, Droz S, Zellweger C, Mühlemann K: Dynamics of hemodialysis catheter colonization by coagulase-negative staphylococci. Infect Control Hosp Epidemiol 26: 567-574, 2005
20. Sehgal AR, Snow RJ, Singer ME, Amini SB, DeOreo PB, Silver MR, Cebul RD: Barriers to inadequate delivery of hemodialysis. Am J Kidney Dis 31: 593-601, 1998
21. Suajanen JN, Brophy DP, Nasser I: Thrombus on indwelling cenral vein catheters: The histopathology of fibrin sheaths. Cardiovasc Intervent Radiolog 23: 194-197, 2000
22. Curelaru I, Gustavsson B, hansson AH, Linder LE, Stenqvist O, Wojciechowski J: Material thrombogenicity in central vein catheterization II: A comparison between plain silicon elastomer and plain polyethylene, long antebrachial catheters. Acta Anaesthesiol Scand 27: 158-164, 1983
23. Mehall JR, Saltzman DA, Jackson RJ: Fibrin sheath enhances central venous catheter infection. Crit Care Med 30: 908-912, 2002
24. National Kidney Foundation Dialysis Outcomes Quality Initiative (KDOQI): NFK-DOQI clinical practice guidelines for vascular access, 2000. Am J Kidney Dis 37[Suppl 1]: S137-S181, 2001
25. Naka T, Egi M, Bellomo R, Baldwin I, Fealy N, Wan L: Resistance of vascular access catheters for continuous renal replacement therapy: An ex vivo evaluation. Int J Artif Organs 31: 905-909, 2008
26. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C: Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant 16: 2072-2074, 2001
27. Vorweg M, Monaca E, Doehn M, Wappler F: The "heparin lock": Cause for iatrogenic coagulopathy. Eur J Anaesthesiol 23: 5053, 2006
28. Markota I, Markota D, Tomic M: Measuring of the heparin leakage into the circulation from central venous catheters: An in vivo study. Nephrol Dial Transplant 24: 1550-1553, 2009
29. Pepper RJ, Gale DP, Wajed J, Bommayya G, Ashby D, McLean A, Laffan M, Maxwell PH: Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodial Int 11: 430-434, 2007
30. Brzosko S, Hryszko T, Malyszko J, Malyszko JS, Mazerska M, Myśliwiec M: Femoral localization and higher ultrafiltration rate but not concentration of heparin used for canal locking of hemodialysis catheter are negative predictors for its malfunction. Am J Nephrol 28: 298-303, 2008
31. Thomas CM, Zhang J, Lim TH, Scott-Douglas N, Hons RB, Hemmelgarn BR: Alberta Kidney Disease Network: Concentration of heparin-locking solution and risk of central venous hemodialysis catheter malfunction. ASAIO J 53: 485-488, 2007
32. Yevzlin AS, Sanchez RJ, Hiatt JG, Washington MH, Wakeen M, Hofmann RM, Becker YT: Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial 20: 351-354, 2007
33. Moritz Ml, Vats A, Ellis D: Systemic anticoagulation and bleeding in children with hemodialysis catheters. Pediatr Nephrol 18: 68-70, 2003
34. Sungur M, Eryuksel E, Yavas S, Bihorac A, Layon AJ, Caruso L: Exit of catheter lock solutions from double lumen acute haemodialysis catheters: An in vitro study. Nephrol Dial Transplant 22: 3533-3537, 2007
35. Holley JL, Bailey S: Catheter lock heparin concentration: Effects on tissue plasminogen activator use in tunneled cuffed catheters. Hemodial Int 11: 96-98, 2007
36. Rioux JP, De Bortoli B, Troyanov S, Madore F: The effect of sodium citrate 4% locking solution for central venous dialysis catheter on the international normalized ratio (INR) value. Nephrol Dial Transplant 23: 1772-1773, 2008
37. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM: Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 17: 2189-2195, 2002
38. Hendrickx L, Kuypers D, Evenepoel P, Maes B, Messiaen T, Vanrenterghem Y: A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. Int J Artif Organs 24: 208-211, 2001
39. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y: A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis catheters. Blood Purif 23: 101-105, 2005
40. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM: Trisodium citrate 4%: An alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 22: 477-483, 2007
41. Macrae JM, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A, Kiaii M: Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol 3: 369-374, 2008
42. Grudzinski L, Quinan P, Kwok S, Pierratos A: Sodium citrate 4% locking solution for central venous dialysis catheters: An effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 22: 471-476, 2007
43. Power A, Duncan N, Singh SK, Brown W, Dalby E, Edwards C, Lynch K, Prout V, Cairns T, Griffith M, McLean A, Palmer A, Taube D: Sodium citrate versus heparin catheter locks for cuffed central venous catheters: A single-center randomized controlled trial. Am J Kidney Dis 53: 1034-1041, 2009
44. U.S. Food and Drug Administration: 2000 Safety Alerts for Human Medicinal Products. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm173095.htm. Accessed December 2009
45. Oran NT, Eser I: Impact of heparin locking frequency on preventing temporary dialysis catheter dysfunction in hemodialysis patients. J Ren Care 34: 199-202, 2008
46. Moran JE, Ash SR: for the ASDIN Clinical Practice Committee: Locking solutions for hemodialysis catheters; heparin and citrate: A position paper by ASDIN. Semin Dial 21: 490-492, 2008
47. Janne d'Othée B, Tham JC, Sjeiman RG: Restoration of patency in failing tunneled hemodialysis catheters: A comparison of catheter exchange, exchange and balloon disruption of the fibrin sheath, and femoral stripping. J Vasc Interv Radiol 17: 1011-1015, 2006
48. Oliver MJ, Mendelssohn DC, Quinn RR, Richardson EP, Rajan DK, Pugash RA, Hiller JA, Kiss AJ, Lok CE: Catheter patency and function after catheter sheath disruption: A pilot study. Clin J Am Soc Nephrol 2: 1201-1206, 2007
49. Coli L, Donati G, Cianciolo G, Raimondi C, Comai G, Panicali L, Nastasi V, Cannarile DC, Gozzetti F, Piccari M, Stefoni S: Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheter (TCC) thrombosis. J Vasc Access 7: 118-122, 2006
50. Willms L, Vercaigne LM: Does warfarin safely prevent clotting of hemodialysis catheters? Semin Dial 21: 71-77, 2008
51. Zellweger M, Bouchard J, Raymond-Carrier S, Laforest-Renald A, Quérin S, Madore F: Systemic anticoagulation and prevention of hemodialysis catheter malfunction. ASAIO J 51: 360-365, 2005
52. Danziger J: Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 3: 1504-1510, 2008
53. McFarland HF, Dinwiddie L, Ferrell J, Forloines-Lynn S: Lytic therapy for central venous catheters for hemodialysis. Nephrol Nurs J 29: 355-360, 2002
54. U.S. Food and Drug Administration: Important drug warning, urokinase. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm113512.htm#99. Accessed December 2009
55. U.S. Food and Drug Administration: Important drug warning, streptokinase. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/default.htm. Accessed December 2009
56. Seddon PA, Hrinya MK, Gaynord MA, Lion CM, Mangold BM, Bruns FJ: Effectiveness of low dose urokinase on dialysis catheter thrombolysis. ASAIO J 44: M559-M561, 1998
57. Gabutti L, Mosconi E, Pellegrini L, Duchini F, Marone C: Chronic and acute consequences of a post-dialysis urokinase lock on permanent hemodialysis catheter function. J Nephrol 19: 183-188, 2006
58. Twardowski ZJ: High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters. Am J Kidney Dis 31: 841-847, 1998
59. Haymond J, Shalansky K, Jastrzebski J: Efficacy of low-dose alteplase for treatment of hemodialysis catheter occlusions. J Vasc Access 6: 76-82, 2005
60. O'Mara NB, Ali S, Bivens K, Sherman RA, Kapoian T: Efficacy of tissue plasminogen activator for thrombolysis in central venous dialysis catheters. Hemodial Int 7: 130-134, 2003
61. Paulsen D, Reisoether A, Aasen M, Fauchald P: Use of tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 64: 468-470, 1993
62. Daeihagh P, Jordan J, Chen J, Rocco M: Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 36: 75-79, 2000
63. Eyrich H, Walton T, Macon EJ, Howe A: Alteplase versus urokinase in restoring blood flow in hemodialysiscatheter thrombosis. Am J Health Syst Pharm 59: 1437-1440, 2002
64. Zacharias JM, Weatherston CP, Spewak CR, Vercaigne LM: Alteplase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother 37: 27-33, 2003
65. MacRae JM, Loh G, Djurdjev O, Shalansky S, Werb R, Levin A, Kiaii M: Short and long alteplase dwells in dysfunctional hemodialysis catheters. Hemodial Int 9: 189-195, 2005
66. Little MA, Walshe JJ: A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 39: 86-91, 2002
67. Dowling K, Sansivero G, Stainken B, Siskin G, Dolen E, Ahn J, Mitchell N: The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters. Nephrol Nurs J 31: 199-200, 2004
68. Savader SJ, Ehrman KO, Porter DJ, Haikal LC, Oteham AC: Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: Critical analysis of 124 procedures. J Vasc Interv Radiol 12: 711-715, 2001
69. Falk A, Samson W, Uribarri J, Vassalotti JA: Efficacy of reteplase in poorly functioning hemodialysis catheters. Clin Nephrol 61: 47-53, 2004
70. Hyman G, England M, Kibede S, Lee P, Willets G: The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center. Nephron Clin Pract 96: c39-c42, 2004
71. Clase CM Crowther MA, Ingram AJ, Cinà CS: Thrombolysis for restoration of patency to haemodialysis central venous catheters: A systematic review. J Thromb Thrombolysis 11: 127-136, 2001
72. Tumlin JA, Goldman J, Spiegel D, Roer D, Adu Ntoso K, Blaney M, Jacobs J, Gillespie BS, Begelman SM: A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3 [Abstract]. J Am Soc Nephrol 20: Abstract F-FC298, 2009
73. Fishbane S, Milligan S, Lempert K, Hertel JE, Wetmore J, Oliver MJ, Blaney M, Gillespie B, Jacobs JR, Begelman SM: A phase III, open-label study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 4 [Abstract]. J Am Soc Nephrol 20: Abstract F-PO1555, 2009
74. Gittins NS: Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: A randomised controlled trial. Arch Intern Med 92: 499-501, 2007
75. McGill RL, Blas A, Bialkin S, Sandroni SE, Marcus RJ: Clinical consequences of heparin-free hemodialysis. Hemodial Int 9: 393-398, 2005
76. McGill RL, Spero JA, Sysak JC, Sandroni SE, Marcus RJ: Tissue plasminogen activator as a hemodialysis catheter locking solution. Haemodial Int 12: 348-351, 2008
77. Dunlay RW, Packard KA, Hilleman DE: Reteplase for dysfunctional hemodialysis catheter clearance. Pharmacotherapy 23: 137-141, 2003
78. Hemmelgarn BR, Moist L, Pilkey RM, Lok C, Dorval M, Tam PY, Berall MJ, LeBlanc M, Toffelmire EB, Manns BJ, Scott-Douglas N: Canadian Hemodialysis Catheter Working Group: Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): Study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrol 7: 8, 2006
79. Steczko J, Ash SR, Nivens DE, Brewer L, Winger RK: Microbial inactivation properties of a new antimicrobial/ antithrombotic catheter lock solution (citrate/methylene blue/parabens). Nephrol Dial Transplant 24: 1937-1945, 2009
80. Weijmer MC, van den Dorpel MA, van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, Schrander-Van der Meer AM, Siegert CE, Stas KJ: CITRATE Study Group: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 16: 2769-2777, 2005
81. Dwyer A: Surface-treated catheters: A review. Semin Dial 21: 542-546, 2008